Advanced SearchSearch Tips
Preventive and Risk Reduction Strategies for Women at High Risk of Developing Breast Cancer: a Review
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Preventive and Risk Reduction Strategies for Women at High Risk of Developing Breast Cancer: a Review
Krishnamurthy, Arvind; Soundara, Viveka; Ramshankar, Vijayalakshmi;
  PDF(new window)
Breast cancer is the most commonly diagnosed invasive cancer among women. Many factors, both genetic and non-genetic, determine a woman`s risk of developing breast cancer and several breast cancer risk prediction models have been proposed. It is vitally important to risk stratify patients as there are now effective preventive strategies available. All women need to be counseled regarding healthy lifestyle recommendations to decrease breast cancer risk. As such, management of these women requires healthcare professionals to be familiar with additional risk factors so that timely recommendations can be made on surveillance/risk-reducing strategies. Breast cancer risk reduction strategies can be better understood by encouraging the women at risk to participate in clinical trials to test new strategies for decreasing the risk. This article reviews the advances in the identification of women at high risk of developing breast cancer and also reviews the strategies available for breast cancer prevention.
Breast cancer risk assessment;risk prediction;risk reduction;strategies;
 Cited by
The role of health policy in the burden of breast cancer in Brazil, BMC Women's Health, 2017, 17, 1  crossref(new windwow)
Antoniou AC, Cunningham AP, Peto J, et al (2008). The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer, 98, 1457-66. crossref(new window)

Bagnardi V, Rota M, Botteri E, et al (2013). Light alcohol drinking and cancer: a meta-analysis. Ann Oncol, 24, 301-8. crossref(new window)

Banerji S, Cibulskis K, Rangel-Escareno C, et al (2012). Sequence analysis of mutations and translocations across breast cancer subtypes. Nature, 486, 405-9. crossref(new window)

Baum M, Budzar AU, Cuzick J, et al (2002). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 359, 2131-9. crossref(new window)

Bertone-Johnson ER, Chen WY, Holick MF, et al (2005). Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev, 14, 1991-7. crossref(new window)

Berx G, Staes K, van Hengel J, et al (1995). Cloning and characterization of the human invasion suppressor gene E-cadherin (CDH1). Genomics, 26, 281-9. crossref(new window)

Boyd NF, Guo H, Martin LJ, et al (2007). Mammographic density and the risk and detection of breast cancer. N Engl J Med, 356, 227-36. crossref(new window)

Bubien V, Bonnet F, Brouste V, et al (2013). High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet, 50, 255-63. crossref(new window)

Cauley JA, Norton L, Lippman ME, et al (2001). Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat, 65, 125-34. crossref(new window)

Chiu SY, Duffy S, Yen AM, et al (2010). Effect of baseline breast density on breast cancer incidence, stage, mortality, and screening parameters: 25-year follow-up of a Swedish mammographic screening. Cancer Epidemiol Biomarkers Prev, 19, 1219-28. crossref(new window)

Chlebowski RT, Anderson GL, Gass M, et al (2010). Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA, 304, 1684-92. crossref(new window)

Claus EB, Risch N, Thompson WD (1994). Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer, 73, 643-51. crossref(new window)

Collaborative Group on Hormonal Factors in Breast Cancer (2002). Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet, 360, 187-95. crossref(new window)

Cuzick J, Sestak I, Bonanni B, et al (2013). Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet, 381, 1827-34. crossref(new window)

Cuzick J, Sestak I, Cawthorn S, et al (2015). Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol, 16, 67-75. crossref(new window)

Cuzick J, Sestak I, Forbes JF, et al (2014). Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet, 383, 1041-8. crossref(new window)

De Felice F, Marchetti C, Musella A, et al (2015). Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Ann Surg Oncol, 22, 2876-80. crossref(new window)

DeSantis CE, Fedewa SA, Goding Sauer A, et al (2015). Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin.

Donnelly LS, Evans DG, Wiseman J, et al (2014). Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Br J Cancer, 110, 1681-7. crossref(new window)

Eliassen AH, Colditz GA, Rosner B, et al (2006). Adult weight change and risk of postmenopausal breast cancer. JAMA, 296, 193-201. crossref(new window)

Ellis MJ, Ding L, Shen D, et al (2012). Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature, 486, 353-60. crossref(new window)

Emaus MJ, van Gils CH, Bakker MF, et al (2014). Weight change in middle adulthood and breast cancer risk in the EPIC-PANACEA study. Int J Cancer, 135, 2887-99. crossref(new window)

Fisher B, Costantino JP, Wickerham DL, et al (2005). Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst, 97, 1652-62. crossref(new window)

Fisher B, Costantino JP, Wickerham DL, et al (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst, 90, 1371-88. crossref(new window)

Gail MH, Costantino JP (2001). Validating and improving models for projecting the absolute risk of breast cancer. J Natl Cancer Inst, 93, 334-5. crossref(new window)

Ghosh K, Vachon CM, Pankratz VS, et al (2010). Independent association of lobular involution and mammographic breast density with breast cancer risk. J Natl Cancer Inst, 102, 1716-23. crossref(new window)

Goss PE, Ingle JN, Ales-Martinez JE, et al (2011). Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med, 364, 2381-91. crossref(new window)

Grady D, Cauley JA, Geiger MJ, et al (2008). Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst, 100, 854-61. crossref(new window)

Hamm RM, Lawler F, Scheid D (1999). Prophylactic mastectomy in women with a high risk of breast cancer. N Engl J Med, 340, 1837-8.

Hartmann LC, Radisky DC, Frost MH, et al (2014). Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res, 7, 211-7. crossref(new window)

Hartmann LC, Sellers TA, Schaid DJ, et al (2001). Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst, 93, 1633-7. crossref(new window)

Howard RA, Leitzmann MF, Linet MS, et al (2009). Physical activity and breast cancer risk among pre- and postmenopausal women in the U.S. Radiologic Technologists cohort. Cancer Causes Control, 20, 323-33. crossref(new window)

King MC, Marks JH, Mandell JB (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 302, 643-6. crossref(new window)

Kotsopoulos J, Olopado OI, Ghadirian P, et al (2005). Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res, 7, 833-43. crossref(new window)

Kuerer HM, Buzdar AU, Mittendorf EA, et al (2011). Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer, 117, 39-47. crossref(new window)

Kurian AW, Sigal BM, Plevritis SK (2010). Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol, 28, 222-31. crossref(new window)

LaCroix AZ, Chlebowski RT, Manson JE, et al (2011). Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA, 305, 1305-14. crossref(new window)

LaCroix AZ, Powles T, Osborne CK, et al (2010). Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst, 102, 1706-15. crossref(new window)

Lazzeroni M, Serrano D, Dunn BK, et al (2012). Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug. Breast Cancer Res, 14, 214. crossref(new window)

Lord SJ, Lei W, Craft P, et al (2007). A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer, 43, 1905-17. crossref(new window)

Mahoney MC, Bevers T, Linos E, et al (2008). Opportunities and strategies for breast cancer prevention through risk reduction. CA Cancer J Clin, 58, 347-71. crossref(new window)

Maresso KC, Tsai KY, Brown PH, et al (2015). Molecular cancer prevention: Current status and future directions. CA Cancer J Clin, 65, 345-83. crossref(new window)

Maunsell E, Goss PE, Chlebowski RT, et al (2014). Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol, 32, 1427-36. crossref(new window)

McTiernan A, Martin CF, Peck JD, et al (2005). Estrogen-plus-progestin use and mammographic density in postmenopausal women: women's health initiative randomized trial. J Natl Cancer Inst, 97, 1366-76. crossref(new window)

Meijers-Heijboer H, van Geel B, van Putten WL, et al (2001). Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med, 345, 159-64. crossref(new window)

Michels KB, Willett WC (2009). The Women's Health Initiative Randomized Controlled Dietary Modification Trial: a post-mortem. Breast Cancer Res Treat, 114, 1-6. crossref(new window)

Nkondjock A, Robidoux A, Paredes Y, et al (2006). Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. Breast Cancer Res Treat, 98, 285-94. crossref(new window)

Pankratz VS, Hartmann LC, Degnim AC, et al (2008). Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol, 26, 5374-9. crossref(new window)

Parmigiani G, Berry D, Aguilar O (1998). Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet, 62, 145-58. crossref(new window)

Pharoah PD, Day NE, Duffy S, et al (1997). Family history and the risk of breast cancer: a systematic review and metaanalysis. Int J Cancer, 71, 800-9. crossref(new window)

Powles TJ, Diem SJ, Fabian CJ, et al (2012). Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene. Breast Cancer Res Treat, 134, 299-306. crossref(new window)

Quante AS, Whittemore AS, Shriver T, et al (2015). Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk. J Natl Cancer Inst, 107.

Rebbeck TR, Friebel T, Lynch HT, et al (2004). Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol, 22, 1055-62. crossref(new window)

Rebbeck TR, Kauff ND, Domchek SM (2009). Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst, 101, 80-7. crossref(new window)

Saslow D, Boetes C, Burke W, et al (2007). American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin, 57, 75-89. crossref(new window)

Shah SP, Roth A, Goya R, et al (2012). The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature, 486, 395-9. crossref(new window)

Stephens PJ, Tarpey PS, Davies H, et al (2012). The landscape of cancer genes and mutational processes in breast cancer. Nature, 486, 400-4. crossref(new window)

Tehard B, Friedenreich CM, Oppert JM, et al (2006). Effect of physical activity on women at increased risk of breast cancer: results from the E3N cohort study. Cancer Epidemiol Biomarkers Prev, 15, 57-64. crossref(new window)

Tice JA, Miglioretti DL, Li CS, et al (2015). Breast density and benign breast disease: risk assessment to identify women at high risk of breast cancer. J Clin Oncol, 33, 3137-43. crossref(new window)

Travis LB, Hill D, Dores GM, et al (2005). Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst, 97, 1428-37. crossref(new window)

Tyrer J, Duffy SW, Cuzick J (2004). A breast cancer prediction model incorporating familial and personal risk factors. Stat Med, 23, 1111-30. crossref(new window)

van Lier MG, Wagner A, Mathus-Vliegen EM, et al (2010). High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol, 105, 1258-65. crossref(new window)

Visvanathan K, Hurley P, Bantug E, et al (2013). Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 31, 2942-62. crossref(new window)

Vogel VG, Costantino JP, Wickerham DL, et al (2006). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 295, 2727-41. crossref(new window)

Vogel VG, Costantino JP, Wickerham DL, et al (2010). Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res, 3, 696-706. crossref(new window)

Vogel VG, Qu Y, Wong M, et al (2009). Incidence of invasive breast cancer in postmenopausal women after discontinuation of long-term raloxifene administration. Clin Breast Cancer, 9, 45-50. crossref(new window)

Wong CS, Lim GH, Gao F, et al (2011). Mammographic density and its interaction with other breast cancer risk factors in an Asian population. Br J Cancer, 104, 871-4. crossref(new window)

Yang XR, Chang-Claude J, Goode EL, et al (2011). Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst, 103, 250-63. crossref(new window)

Zhang Y, Zhang M, Yuan X, et al (2015). Association between ESR1 PvuII, XbaI, and P325P polymorphisms and breast cancer susceptibility: a meta-analysis. Med Sci Monit, 21, 2986-96. crossref(new window)